Crispr Therapeutics AG (NASDAQ:CRSP) – Oppenheimer issued their Q1 2020 EPS estimates for Crispr Therapeutics in a research report issued to clients and investors on Tuesday, November 12th, Zacks Investment Research reports. Oppenheimer analyst S. Tuerkcan anticipates that the company will earn ($0.87) per share for the quarter. Oppenheimer has a “Outperform” rating and a $80.00 price objective on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ FY2021 earnings at ($4.29) EPS, FY2022 earnings at ($4.70) EPS and FY2023 earnings at ($1.07) EPS.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%.
Several other brokerages have also issued reports on CRSP. BidaskClub upgraded Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 30th. William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Roth Capital increased their target price on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Chardan Capital reissued a “buy” rating and issued a $72.50 price target on shares of Crispr Therapeutics in a research report on Monday, November 18th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a research note on Tuesday, November 26th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $69.54.
Shares of CRSP opened at $72.37 on Friday. The stock has a 50-day moving average of $54.81 and a 200-day moving average of $47.38. The company has a market cap of $4.00 billion, a PE ratio of -21.04 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics has a one year low of $22.22 and a one year high of $74.00.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $390,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. NEXT Financial Group Inc grew its holdings in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after acquiring an additional 549 shares in the last quarter. Benjamin Edwards Inc. boosted its position in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after purchasing an additional 268 shares during the last quarter. Coastal Investment Advisors Inc. purchased a new position in Crispr Therapeutics in the third quarter worth $26,000. US Bancorp DE boosted its position in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares during the last quarter. Finally, BSW Wealth Partners bought a new position in Crispr Therapeutics in the 2nd quarter valued at $39,000. Hedge funds and other institutional investors own 49.81% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.